BioNTech SE (NASDAQ:BNTX) Shares Bought by Investmentaktiengesellschaft Fuer Langfristige Investoren TGV

Investmentaktiengesellschaft Fuer Langfristige Investoren TGV raised its position in shares of BioNTech SE (NASDAQ:BNTX) by 26.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,500 shares of the company’s stock after buying an additional 3,000 shares during the period. BioNTech comprises 0.1% of Investmentaktiengesellschaft Fuer Langfristige Investoren TGV’s holdings, making the stock its 18th largest position. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV’s holdings in BioNTech were worth $1,530,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of BioNTech in the 4th quarter valued at about $274,000. PARUS FINANCE UK Ltd increased its holdings in shares of BioNTech by 1.2% in the 4th quarter. PARUS FINANCE UK Ltd now owns 25,974 shares of the company’s stock valued at $2,741,000 after purchasing an additional 312 shares during the period. Harding Loevner LP acquired a new position in BioNTech in the fourth quarter worth approximately $410,984,000. Caas Capital Management LP acquired a new position in BioNTech in the fourth quarter worth approximately $317,000. Finally, Neuberger Berman Group LLC acquired a new position in BioNTech in the fourth quarter worth approximately $1,562,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on BNTX. JPMorgan Chase & Co. dropped their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. TD Cowen increased their price target on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. UBS Group lowered their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Finally, Evercore ISI assumed coverage on BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, BioNTech has an average rating of “Hold” and a consensus target price of $111.70.

BioNTech Stock Down 4.1 %

Shares of NASDAQ:BNTX traded down $3.92 during trading on Friday, hitting $92.08. 768,301 shares of the company’s stock traded hands, compared to its average volume of 984,847. BioNTech SE has a 52 week low of $85.21 and a 52 week high of $125.83. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The company has a market cap of $21.89 billion, a price-to-earnings ratio of 184.16 and a beta of 0.27. The company has a 50-day moving average price of $92.81 and a 200-day moving average price of $95.79.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The firm had revenue of $203.69 million during the quarter, compared to the consensus estimate of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. As a group, research analysts forecast that BioNTech SE will post -2.01 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.